|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-7-1
|
|
pubmed:abstractText |
Herpes zoster is the most common infection in patients treated with bortezomib-containing regimens for multiple myeloma. Some clinical trials have reported on the use of acyclovir prophylaxis to decrease the incidence of herpes zoster. However, the appropriate acyclovir dose and duration of prophylaxis remain unclear. The primary objective of this study was to evaluate the efficacy of continuous oral 200 mg/day acyclovir prophylaxis and the secondary objective was to determine the risk factors for developing herpes zoster.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
876-81
|
|
pubmed:meshHeading |
pubmed-meshheading:21616919-Acyclovir,
pubmed-meshheading:21616919-Administration, Oral,
pubmed-meshheading:21616919-Aged,
pubmed-meshheading:21616919-Aged, 80 and over,
pubmed-meshheading:21616919-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21616919-Antiviral Agents,
pubmed-meshheading:21616919-Boronic Acids,
pubmed-meshheading:21616919-Drug Administration Schedule,
pubmed-meshheading:21616919-Female,
pubmed-meshheading:21616919-Herpes Zoster,
pubmed-meshheading:21616919-Herpesvirus 3, Human,
pubmed-meshheading:21616919-Humans,
pubmed-meshheading:21616919-Male,
pubmed-meshheading:21616919-Middle Aged,
pubmed-meshheading:21616919-Multiple Myeloma,
pubmed-meshheading:21616919-Pyrazines,
pubmed-meshheading:21616919-Recurrence,
pubmed-meshheading:21616919-Retrospective Studies,
pubmed-meshheading:21616919-Risk Factors,
pubmed-meshheading:21616919-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
|
|
pubmed:affiliation |
Division of Hematology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Aichi 4918558, Japan. taoki-cib@umin.net
|
|
pubmed:publicationType |
Journal Article
|
